Nasal Foralumab for the Treatment of Progression Independent of Relapses in Patients With Nonactive Secondary Progressive Multiple Sclerosis

Tanuja Chitnis; Tarun Singhal; Jonathan Zurawski; Taylor J. Saraceno; Niveditha Gopalakrishnan; Lauren E. Cain; Brenna A. LaBarre; D. A. King; Regan W. Bergmark; Alice Z. Maxfield; Steven Cicero; Hong Pan; Shipra Dubey; Steven Vaquerano; Caleb Hansel; B.F Healy; Shrishti Saxena; Hrishikesh A. Lokhande; Moogeh Baharnoori; Evan Madill; Manali Shah Sheth; Rachel Rodin; Jessica Ye; Nancy Clementi; William A. Clementi; Howard L. Weiner

doi:10.1212/nxi.0000000000200543

Abstract

This is the authors' abstract. We don't add key points for this paper.

Progression independent of relapses (PIRA) is a major therapeutic challenge in multiple sclerosis (MS). Nasal anti-CD3 treats animal models of progressive MS by inducing regulatory T cells (Tregs) that suppress CNS inflammation and lessen clinical disease.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Chitnis et al. (2026) studied this question.

synapsesocial.com/papers/6a1bf66d1567d2fc4d5f5543 https://doi.org/10.1212/nxi.0000000000200543

View Full Paper

Ask AI

Bookmark

Share

Nasal Foralumab for the Treatment of Progression Independent of Relapses in Patients With Nonactive Secondary Progressive Multiple Sclerosis

Abstract

Ask about this paper

Discussion

Cite This Study

Nasal Foralumab for the Treatment of Progression Independent of Relapses in Patients With Nonactive Secondary Progressive Multiple Sclerosis

Abstract

Ask about this paper

Discussion

Cite This Study

Keep reading

Keep reading